Markets

Agios (AGIO) Reports Narrower-than-Expected Loss in Q1 - Tale of the Tape

Agios Pharmaceuticals, Inc. ( AGIO ) is a development-stage biopharmaceutical company with a focus on the development of a potential treatment for cancer and rare genetic disorders of metabolism. This Cambridge, MA-based company has three candidates in its pipeline, namely, AG-221 (IDH2 mutant inhibitor - advanced hematologic malignancies like acute myelogenous leukemia/AML and solid tumors), AG-120 (IDH1 mutant inhibitor - AML and solid tumors) and AG-348 (pyruvate kinase deficiency).

Revenues at Agios mainly consist of collaboration revenues under its agreement with Celgene Corporation. Agios is in collaboration with Celgene for AG-221 and AG-120.

With Agios not having any approved products in its portfolio, investor focus should remain on pipeline updates since a number of pipeline related activities are lined up for the rest of 2015.

Agios has a disappointing earnings track record with the company delivering negative earnings surprises in three of the last four trailing quarters. However, the company has a positive average surprise of 15.10%. Estimate revisions are, however, flat for 2015.

Currently, Agios has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: Agios posted narrower-than-expected first quarter loss. Our consensus called for a loss of 89 cents per share, and the company reported a loss of 13 cents per share.

Revenue: Revenues also surpassed expectations. Agios posted revenues of $14.6 million, compared to our consensus estimate of $10 million.

Key Stats: Agios continues to progress with its pipeline. The company also plans to initiate combination studies on AG-221 for the treatment for patients with AML and a broad range of hematologic malignancies in the second half of 2015. The company also has plans to initiate a phase III study on the candidate in relapsed/refractory AML patients in the second half of 2015. Agios also has initiate three expansion cohorts as part of an ongoing phase I study on AG-120 (hematologic malignancies) and intends to present first data from the phase I trial on AG-120 in the advanced solid tumors indication in the second half of 2015.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AGIOS PHARMACT (AGIO): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AGIO

Other Topics

Investing Stocks